MOUNTAIN VIEW, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's fourth quarter 2017 financial results will be released before market open on Friday, March 9, 2018 . ChemoCentryx executive management will host a conference call

-- CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients --  -- Clinical findings to be presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium -- MOUNTAIN VIEW, Calif. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.

MOUNTAIN VIEW, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced the appointment of William (Bill) Fairey as Executive Vice President and

-- ChemoCentryx to Receive $50 Million Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis -- -- Company Also Enters into $50 Million Growth Capital Financing Agreement with Hercules Capital -- MOUNTAIN

Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney Health Alliance ChemoCentryx to receive regulatory milestone payment from VFMCRP VIFOR FRESENIUS MEDICAL

MOUNTAIN VIEW, Calif. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer,

MOUNTAIN VIEW, Calif. , Nov. 17, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer,

-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 -- -- Patient enrollment ongoing in registration-supporting trial for avacopan in the treatment C3 Glomerulopathy (C3G) -- -- Plan to launch registration-supporting trial for CCX140 in the treatment of Focal

-- Rapid reduction in kidney inflammation following avacopan treatment in patients with ANCA-Associated Vasculitis revealed by analysis of markers of kidney damage -- -- Podocyte protection demonstrated with CCR2 inhibitor CCX140, supporting differentiated potential treatment option for patients

MOUNTAIN VIEW, Calif. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's third quarter 2017 financial results will be released